ZYUS Life Sciences (TSXV:ZYUS) Notes Receivable: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZYUS ZYUS Life Sciences Corp TSXV:ZYUS
16 GF Score
Price C$0.50
! 6 Warning Signs
View Full Analysis

What is ZYUS Life Sciences Notes Receivable?

ZYUS Life Sciences TSXV:ZYUS 16 Notes Receivable is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSXV:ZYUS with a GF Score™ of 16/100. The stock has 6 warning signs investors should review.

ZYUS Life Sciences's Notes Receivable for the quarter that ended in Mar. 2026 was C$0.00 Mil.

ZYUS Life Sciences Notes Receivable Related Terms

ZYUS Life Sciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Notes Receivable Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00 0.00

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:ZYUS
16GF Score
ZYUS Life Sciences Corp TSXV:ZYUS
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZYUS Life Sciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of C$0.00 Mil mean?
ZYUS Life Sciences (TSXV:ZYUS) has a Notes Receivable of C$0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' Notes Receivable too high?
ZYUS Life Sciences' current Notes Receivable is C$0.00 Mil. Overall, ZYUS Life Sciences has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does ZYUS Life Sciences' Notes Receivable compare to ZTS and UTHR?
ZYUS Life Sciences' Notes Receivable of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current Notes Receivable is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
ZYUS Life Sciences (TSXV:ZYUS) has a current Notes Receivable of C$0.00 Mil. The current Notes Receivable is C$0.00 Mil. ZYUS Life Sciences' overall GF Score™ is 16/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For ZYUS Life Sciences (TSXV:ZYUS), the current Notes Receivable is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZLSCF:USA
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
16GF Score

Get the complete analysis for TSXV:ZYUS

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price